Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187

Angiogenesis in cancer, vascular, rheumatoid and other disease

Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,586

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 3×

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486

Angiogenesis in health and disease

Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276

Microenvironmental regulation of metastasis

Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684

Tumorigenesis and the angiogenic switch

Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559

Angiogenesis in life, disease and medicine

Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482

Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis

Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007

Modes of resistance to anti-angiogenic therapy

Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 2×

Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761

Angiogenesis as a therapeutic target

Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653

Molecular regulation of vessel maturation

Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529

Regulation of angiogenesis by hypoxia: role of the HIF system

Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272

Angiogenesis: an organizing principle for drug discovery?

Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246

Distinct role of macrophages in different tumor microenvironments

Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225

Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF

Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937

Eicosanoids and cancer

Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709

VEGF-targeted therapy: mechanisms of anti-tumour activity

Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673

The role of myeloid cells in the promotion of tumour angiogenesis

Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559

Clinical translation of angiogenesis inhibitors

Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517

Targeting the dynamic HSP90 complex in cancer

Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261

Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189

Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110

Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer

Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056

HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α

Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054

Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061355 · Cited by 1,048

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 862

Signal Transduction and Signal Modulation by Cell Adhesion Receptors: The Role of Integrins, Cadherins, Immunoglobulin-Cell Adhesion Molecules, and Selectins

Aplin, A. E., Howe, A., Alahari, S. K., & Juliano, R. L. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01359-0 · Cited by 847

Targeting of drugs and nanoparticles to tumors

Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798

Targeting the tumour vasculature: insights from physiological angiogenesis

Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion

Bourboulia, D., & Stetler-Stevenson, W. G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.05.002 · Cited by 710

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700

Angiopoietins in angiogenesis

Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644

The angiogenic switch in carcinogenesis

Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625

Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis

Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611

The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases

Whitelock, J. M., Murdoch, A. D., Iozzo, R. V., & Underwood, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.10079 · Cited by 597

Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness

Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0785 · Cited by 596

Tumour vascularization: sprouting angiogenesis and beyond

Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583

Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 570

Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy

Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

Fournier, P. G. J., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M. C., & Clézardin, P. (2002) · PubMed · Cited by 562

Endogenous Inhibitors of Angiogenesis

Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553

The tumor microenvironment and its contribution to tumor evolution toward metastasis

Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 531

Cancer associated fibroblasts: the dark side of the coin.

Cirri, P., & Chiarugi, P. (2011) · Europe PMC (PubMed Central) · Cited by 513

Complex roles of tissue inhibitors of metalloproteinases in cancer

Jiang, Y., Goldberg, I. D., & Shi, Y. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205291 · Cited by 507

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N. T., Bancroft, C. C., Sausville, E. A., Adams, J., Elliott, P. J., & Waes, C. V. (2001) · PubMed · Cited by 473

Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages

Visentin, B., Vekich, J. A., Sibbald, B. J., Cavalli, A. L., Moreno, K. M., Matteo, R. G., Garland, W. A., Lu, Y., Yu, S., Hall, H. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.023 · Cited by 463

Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis

Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455

Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis

Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., Kahn, C. R., Sonenberg, N., Hynes, R. O., & Kalluri, R. (2002) · Science · doi:10.1126/science.1065298 · Cited by 438

Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9.

Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002) · PubMed · Cited by 423

Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead

van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420

Angiogenesis and apoptosis

Folkman, J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00133-5 · Cited by 415

Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412

Endostatin's Antiangiogenic Signaling Network

Abdollahi, A., Hahnfeldt, P., Maercker, C., Gröne, H.-J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L., & Huber, P. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00102-9 · Cited by 393

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388

Insulin-like growth factor I is required for vessel remodeling in the adult brain.

Lopez-Lopez, C., LeRoith, D., & Torres-Aleman, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400337101 · Cited by 385

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K. E., Stransky, N., Greulich, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020351 · Cited by 369

Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis

Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3255 · Cited by 355

An overview of small-molecule inhibitors of VEGFR signaling

Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350

Management of hypertension in angiogenesis inhibitor-treated patients

Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 347

CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer

Wang, D., Wang, H., Brown, J., Daikoku, T., Ning, W., Shi, Q., Richmond, A., Strieter, R., Dey, S. K., & DuBois, R. N. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052124 · Cited by 338

Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix Metalloproteinases

Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F., Millar, H., Rafferty, P., Bugelski, P., & Yan, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3605 · Cited by 337

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334

Tumour macrophages as potential targets of bisphosphonates

Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0450 · Cited by 320

Resveratrol Isolated from Polygonum cuspidatum Root Prevents Tumor Growth and Metastasis to Lung and Tumor-Induced Neovascularization in Lewis Lung Carcinoma-Bearing Mice

Kimura, Y., & Okuda, H. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.6.1844 · Cited by 313

v Integrins in Angiogenesis and Cancer

Weis, S. M., & Cheresh, D. A. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006478 · Cited by 311

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304

Cell adhesion and angiogenesis.

Bischoff, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119168 · Cited by 291

Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway

Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., Holen, I., Mönkkönen, H., Boccadoro, M., Forni, G., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00926.x · Cited by 275

Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates

Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256 · cited 4×

Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity

Wei, D., Wang, L., He, Y., Xiong, H. Q., Abbruzzese, J. L., & Xie, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1945 · Cited by 246

Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma

Huang, D., Ding, Y., Li, Y., Luo, W.-M., Zhang, Z.-F., Snider, J., VandenBeldt, K., Qian, C.-N., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3722 · Cited by 240

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Lee, J. S., Hirsh, V., Park, K., Qin, S., Blajman, C. R., Perng, R.-P., Chen, Y.-M., Emerson, L., Langmuir, P., & Manegold, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1709 · Cited by 230

The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584

Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., & Pili, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0540 · Cited by 229

Predicting benefit from anti-angiogenic agents in malignancy

Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228

Resveratrol Suppresses Colitis and Colon Cancer Associated with Colitis

Cui, X., Jin, Y., Hofseth, A. B., Pena, E., Habiger, J., Chumanevich, A., Poudyal, D., Nagarkatti, M., Nagarkatti, P. S., Singh, U. P., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0117 · Cited by 219

CXC chemokines in angiogenesis of cancer

Strieter, R. M., Belperio, J. A., Phillips, R. J., & Keane, M. P. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.006 · Cited by 218

Antivascular Actions of Microtubule-Binding Drugs

Schwartz, E. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2710 · Cited by 218

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

Cohen, M. H., Gootenberg, J., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-356 · Cited by 217

CXCR2 antagonists for the treatment of pulmonary disease

Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214

Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy

Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Gröne, H.-J., Hallahan, D. E., Reisfeld, R. A., Debus, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1223 · Cited by 205

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

Rudge, J. S., Holash, J., Hylton, D., Russell, M., Jiang, S., Leidich, R., Papadopoulos, N., Pyles, E. A., Torri, A., Wiegand, S. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708865104 · Cited by 203

Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.

Leek, R., Talks, K., Pezzella, F., Turley, H., Campo, L., Brown, N. S., Bicknell, R., Taylor, M., Gatter, K. C., & Harris, A. L. (2002) · PubMed · Cited by 199

A monoclonal antibody to vascular endothelial–cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

Corada, M., Zanetta, L., Orsenigo, F., Breviario, F., Lampugnani, M. G., Bernasconi, S., Liao, F., Hicklin, D. J., Bohlen, P., & Dejana, E. (2002) · Blood · doi:10.1182/blood.v100.3.905 · Cited by 195

Tumor Inflammatory Angiogenesis and Its Chemoprevention

Albini, A., Tosetti, F., Benelli, R., & Noonan, D. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3473 · Cited by 194

Type IV collagen-derived angiogenesis inhibitors

Mundel, T. M., & Kalluri, R. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.005 · Cited by 194

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

Haura, E. B., Tanvetyanon, T., Chiappori, A., Williams, C., Simon, G., Antonia, S., Gray, J., Litschauer, S., Tetteh, L., Neuger, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4029 · Cited by 194

Endogenous inhibitors of angiogenesis

Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

Zhao, G., Li, W.-Y., Chen, D., Henry, J. R., Li, H.-Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0306 · Cited by 189

Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug

Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs336 · Cited by 188

Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression

Hamano, Y., Sugimoto, H., Soubasakos, M. A., Kieran, M., Olsen, B. R., Lawler, J., Sudhakar, A., & Kalluri, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3126 · Cited by 185

Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis

Mizukami, Y., Kohgo, Y., & Chung, D. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0111 · Cited by 184

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

Shinohara, E. T., Cao, C., Niermann, K., Mu, Y., Zeng, F., Hallahan, D. E., & Lu, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208715 · Cited by 183

‘Accidental’ anti-angiogenic drugs

Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182

FGF-dependent regulation of VEGF receptor 2 expression in mice

Murakami, M., Nguyen, L. T., Hatanaka, K., Schachterle, W., Chen, P.-Y., Zhuang, Z. W., Black, B. L., & Simons, M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44762 · Cited by 181

M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis

Zhou, H., Roy, S., Cochran, E., Zouaoui, R., Chu, C. L., Duffner, J., Zhao, G., Smith, S., Galcheva-Gargova, Z., Karlgren, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021106 · Cited by 178

The antineoplastic role of bisphosphonates: from basic research to clinical evidence

Santini, D., Vespasiani Gentilucci, U., Vincenzi, B., Picardi, A., Vasaturo, F., La Cesa, A., Onori, N., Scarpa, S., & Tonini, G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg401 · Cited by 171

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

Nawrocki, S. T., Bruns, C. J., Harbison, M. T., Bold, R. J., Sweeney‐Gotsch, B., Abbruzzese, J. L., Elliott, P. J., Adams, J., & McConkey, D. J. (2002) · PubMed · Cited by 170

Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients

Santini, D., Vincenzi, B., Galluzzo, S., Battistoni, F., Rocci, L., Venditti, O., Schiavon, G., Angeletti, S., Uzzalli, F., Caraglia, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0551 · Cited by 169

A review on pro- and anti-angiogenic factors as targets of clinical intervention

BOUIS, D., KUSUMANTO, Y., MEIJER, C., MULDER, N., & HOSPERS, G. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2005.10.006 · Cited by 165

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

Dredge, K., Hammond, E., Handley, P., Gonda, T. J., Smith, M. T., Vincent, C., Brandt, R., Ferro, V, & Bytheway, I. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.11 · Cited by 162

Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia

Franco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A. M., Brown, A. S., Hicklin, D. J., Foster, F. S., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3295 · Cited by 162

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 153

Lipid Mediators in Life Science

Murakami, M. (2011) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.60.7 · Cited by 153

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

Liu, C., Lee, P., Lin, D., Wu, C.-C., Jeng, L., Lin, P.-W., Mok, K., Lee, W., Yeh, H., Ho, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.023 · Cited by 151

Vessel Co-Option: How Tumors Obtain Blood Supply in the Absence of Sprouting Angiogenesis

Leenders, W. P. J., Küsters, B., & de Waal, R. M. W. (2002) · Endothelium · doi:10.1080/10623320212006 · Cited by 150

Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?

Penel, N., Adenis, A., & Bocci, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.009 · Cited by 149

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

Hsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 149

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

Taeger, J., Moser, C., Hellerbrand, C., Mycielska, M. E., Glockzin, G., Schlitt, H. J., Geissler, E. K., Stoeltzing, O., & Lang, S. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0312 · Cited by 148

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

Argiris, A. E., Kotsakis, A. P., HOANG, T. N., Worden, F. P., Savvides, P. S., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds245 · Cited by 148

Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties

Bono, F., Smet, F. D., Herbert, C., Bock, K. D., Γεωργιάδου, Μ., Fons, P., Tjwa, M., Alcouffe, C., Ny, A., Bianciotto, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.019 · Cited by 146

Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling

Herbert, C., Schieborr, U., Saxena, K., Juraszek, J., Smet, F. D., Alcouffe, C., Bianciotto, M., Saladino, G., Sibrac, D., Kudlinzki, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.018 · Cited by 134

Side effects of anti-angiogenic drugs

Elice, F., & Rodeghiero, F. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70016-6 · Cited by 133

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Hariharan, S., Gustafson, D. L., Holden, S. N., McConkey, D. J., Davis, D. W., Morrow, M., Basche, M., Gore, L., Zang, C., O’Bryant, C. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm140 · Cited by 130

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Angevin, E., Lopez-Martin, J. A., Lin, C., Gschwend, J. E., Harzstark, A. L., Castellano, D., Soria, J., Sen, P., Chang, J. E., Shi, M. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2885 · Cited by 129

A systems approach to cancer therapy: Antiangiogenics + Standard Cytotoxics ? Mechanism(s) of Interaction

Teicher, B. A. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437479 · Cited by 125

Intussusceptive microvascular growth in tumors

Ribatti, D., & Djonov, V. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.040 · Cited by 124

Integrins: Signaling, disease, and therapy

Huveneers, S., Truong, H. H., & Danen, E. H. J. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701481808 · Cited by 121

A preclinical and clinical review of aflibercept for the management of cancer

Gaya, A. M., & Tse, V. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.008 · Cited by 119

Permeability properties of tumor surrogate blood vessels induced by VEGF-A

Nagy, J. A., Feng, D., Vasile, E., Wong, W. H., Shih, S., Dvořàk, A. M., & Dvorak, H. F. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700436 · Cited by 119

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis

Sanderson, S., Valenti, M. R., Gowan, S. M., Patterson, L., Ahmad, Z., Workman, P., & Eccles, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0439 · Cited by 118

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Argiris, A. E., Karamouzis, M. V., Gooding, W. E., Branstetter, B. F., Zhong, S., Raez, L. E., Savvides, P. S., & Romkes, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3591 · Cited by 117

PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

di Tomaso, E., London, N. R., Fuja, D. G., Logie, J. J., Tyrrell, J. A., Kamoun, W. S., Munn, L. L., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005123 · Cited by 116

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

Manthey, C. L., Johnson, D. L., Illig, C. R., Tuman, R. W., Zhao, Z., Baker, J. F., Chaikin, M. A., Donatelli, R. R., Franks, C. F., Zeng, L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0255 · Cited by 115

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

Fang, P., Hu, J., Cheng, Z., Liu, Z., Wang, J., & Jiao, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049717 · Cited by 112

Inhibition of heat shock protein 90 impairs epidermal growth factor–mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

Lang, S. A., Klein, D., Moser, C., Gaumann, A. K. A., Glockzin, G., Dahlke, M. H., Dietmaier, W., Bolder, U., Schlitt, H. J., Geissler, E. K., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0628 · Cited by 112

Bcl-2 Acts in a Proangiogenic Signaling Pathway through Nuclear Factor-κB and CXC Chemokines

Karl, E., Warner, K. A., Zeitlin, B. D., Kaneko, T., Wurtzel, L., Jin, T., Chang, J., Wang, S., Wang, C.-Y., Strieter, R. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0140 · Cited by 111

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

Manegold, P. C., Paringer, C., Kulka, U., Krimmel, K., Eichhorn, M., Wilkowski, R., Jauch, K., Guba, M. O., & Bruns, C. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0955 · Cited by 111

Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

Lord, R., Nair, S., Schache, A. G., Spicer, J. F., Somaihah, N., Khoo, V. S., & Pandha, H. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.143 · Cited by 110

The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1

Qin, L., Zhao, D., Xu, J., Ren, X., Terwilliger, E. F., Parangi, S., Lawler, J., Dvorak, H. F., & Zeng, H. (2013) · Blood · doi:10.1182/blood-2012-07-443903 · Cited by 110

Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer

Yao, M., Zhou, W., Sangha, S., Albert, A., Chang, A. J., Liu, T. C., & Wolfe, M. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1696 · Cited by 104

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605814 · Cited by 104

Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities

Polverini, P. J. (2002) · Journal of Dental Education · doi:10.1002/j.0022-0337.2002.66.8.tb03565.x · Cited by 101

Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer

Han, J.-Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji251 · Cited by 99 · cited 1×

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

Kreisl, T. N., McNeill, K. A., Sul, J., Iwamoto, F. M., Shih, J. H., & Fine, H. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos265 · Cited by 96

Tumor Angiogenesis as a Target for Dietary Cancer Prevention

Li, W. W., Li, V. W., Hutnik, M., & Chiou, A. S. (2011) · Journal of Oncology · doi:10.1155/2012/879623 · Cited by 95

Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study

Hsu, C., Yang, T., Huo, T., Hsieh, R., Yu, C., Hwang, W.-S., Hsieh, T., Huang, W.-T., Chao, Y., Meng, R., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.013 · Cited by 94

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature

May, C., Doody, J. F., Abdullah, R., Balderes, P. J., Xu, X., Chen, C. P., Zhu, Z., Shapiro, L. S., Kussie, P. H., Hicklin, D. J., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0010 · Cited by 94

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Drevs, J., Fakler, J., Eisele, S., Medinger, M., Bing, G., Esser, N., Marmé, D., & Unger, C. (2004) · PubMed · Cited by 94

A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains

Martens, E., Leyssen, A., Aelst, I. V., Fiten, P., Piccard, H., Hu, J., Descamps, F. J., den Steen, P. E. V., Proost, P., Damme, J. V., et al. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.10.012 · Cited by 93

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Han, L. Y., Landen, C., Trevino, J., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T.-J., Merritt, W., Coleman, R., Gershenson, D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1410 · Cited by 91

Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degeneration

Sabbadini, R. A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01118.x · Cited by 90

A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis

Baka, S., Clamp, A. R., & Jayson, G. C. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.867 · Cited by 90

Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

Montero, A. J., Escobar, M., Lopes, G. D. L., Jr., Glück, S., & Vogel, C. L. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0202-z · Cited by 89

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

Besse, B., Tsao, L. C., Chao, D. T., Fang, Y., Soria, J., Almokadem, S., & Belani, C. P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds281 · Cited by 89

Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression

Li, D., Williams, J. I., & Pietras, R. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205410 · Cited by 89

Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats.

Tei, K., Kawakami-Kimura, N., Taguchi, O., Kumamoto, K., Higashiyama, S., Taniguchi, N., Toda, K., Kawata, R., Hisa, Y., & Kannagi, R. (2002) · PubMed · Cited by 86

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes

Summy, J. M., Trevino, J. G., Lesslie, D. P., Baker, C. H., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Metcalf, C. A., Keats, J. A., Sawyer, T. K., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0171 · Cited by 83

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

Briasoulis, E. C., Aravantinos, G., Kouvatseas, G., Pappas, P., Biziota, E., Sainis, I., Makatsoris, T., Varthalitis, I. I., Xanthakis, I., Vassias, A., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-263 · Cited by 77

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

Zhang, C. C., Yan, Z., Zhang, Q., Kuszpit, K. K., Zasadny, K. R., Qiu, M., Painter, C. L., Wong, A., Kraynov, E. A., Arango, M. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1343 · Cited by 77

Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies

Reardon, D. A., & Cheresh, D. (2011) · Genes & Cancer · doi:10.1177/1947601912450586 · Cited by 76

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

Navid, F., Baker, S. D., McCarville, M. B., Stewart, C. F., Billups, C. A., Wu, J., Davidoff, A. M., Spunt, S. L., Furman, W. L., McGregor, L. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1897 · Cited by 75

Nanoparticulate Delivery System Targeted to Tumor Neovasculature for Combined Anticancer and Antiangiogenesis Therapy

Wang, Z., Chui, W., & Ho, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0308-2 · Cited by 74

Chemokines in tumor-associated angiogenesis

Gerber, P. A., Hippe, A., Buhren, B. A., Müller, A., & Homey, B. (2009) · Biological Chemistry · doi:10.1515/bc.2009.144 · Cited by 74

(−)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling–Mediated Angiogenesis

Pang, X., Wu, Y., Wu, Y., Lu, B., Chen, J., Wang, J., Yi, Z., Qu, W., & Liu, M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0936 · Cited by 74

Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth

Johnstone, K. D., Karoli, T., Liu, L., Dredge, K. S., Copeman, E., Li, C. P., Davis, K., Hammond, E., Bytheway, I., Kostewicz, E. S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901449m · Cited by 74

Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts

Zhao, W.-M., Wang, L., Park, H., Chhim, S., Tanphanich, M., Yashiro, M., & Kim, K. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0531 · Cited by 73

Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2

MacLauchlan, S., Yu, J., Parrish, M. C., Asoulin, T. A., Schleicher, M., Krady, M. M., Zeng, J., Huang, P. L., Sessa, W. C., & Kyriakides, T. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104357108 · Cited by 71

Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity

Eikesdal, H. P., Sugimoto, H., Birrane, G., Maeshima, Y., Cooke, V. G., Kieran, M. W., & Kalluri, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807055105 · Cited by 68

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Garofalo, A., Naumova, E., Manenti, L., Ghilardi, C., Ghisleni, G., Caniatti, M., Colombo, T., Cherrington, J. M., Scanziani, E., Nicoletti, M. I., et al. (2003) · PubMed · Cited by 63

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Manegold, C., Vansteenkiste, J., Cardenal, F., Schuette, W., Woll, P. J., Ulsperger, E., Kerber, A. U., Eckmayr, J., & von Pawel, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9842-6 · Cited by 63

Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence

Willis, L., El‐Remessy, A. B., Somanath, P. R., DeRemer, D. L., & Fagan, S. C. (2010) · Clinical Science · doi:10.1042/cs20100389 · Cited by 61

The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis

Naumova, E., Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E., Scanziani, E., Eccles, S. A., Bani, M. R., & Giavazzi, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1615 · Cited by 61

A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

Wang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C., & Kim, K. J. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0813 · Cited by 60

The Role of Angiogenesis in Cancer Treatment

Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656

Molecular targeted therapy for anticancer treatment

Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer

Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396

Recent discoveries of anticancer flavonoids

Raffa, D., Maggio, B., Raimondi, M. V., Plescia, F., & Daidone, G. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.034 · Cited by 339

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers

Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299